Fig. 4

Effect of IL-33 administration on MC-mediated IMQ-induced psoriasis-like dermatitis. a Skin lesion tissues of IMQ-induced WT mice and Vaseline controls co-labelled for IL-33 (red) and Avidin (green). Merged image shows co-localisation of the two markers (yellow). Sections were counterstained with DAPI (blue) for nuclear staining. Scale bar = 100 μm. b Schematic representation of the protocol design for the treatment with recombinant mouse IL-33 and IMQ. c Representative photographs of the lesioned skin of mice from each group on Days 0, 4 and 6. d Disease severity scoring of each group, based on scaling, erythema, and skin thickness, from Day 0 to Day 6. The upper marker represents the results of WT/IMQ-PBS vs. WT/IMQ-IL-33, and the lower one represents the results of Wsh/IMQ-PBS vs. Wsh/IMQ-IL-33. e Representative haematoxylin & eosin staining of skin sections of mice from each group on Days 4 and 6. Scale bar = 100 μm. f Epidermal thickness measurements of skin sections for each group (n = 3). Results shown are representative of three independent experiments. Data are represented by mean ± SEM; * p < 0.05, ** p < 0.01, and *** p < 0.001